Clinical Trial Update: An Extension Study of HGT-HIT-045 Evaluating Long-Term Safety and Clinical Outcomes of Idursulfase-IT in Conjunction With Elaprase in Pediatric Participants With Hunter Syndrome and Cognitive Impairment [Phase 1, Phase 2]

View source ↗

Summary

An extension Phase 1/2 study evaluating the long-term safety and clinical outcomes of combining Idursulfase-IT with Elaprase in pediatric participants with Hunt…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hunter Syndrome
• Mucopolysaccharidosis Type Ii

Drugs mentioned

• Elaprase (idursulfase)
• Idursulfase-IT (idursulfase-IT)

Snippet

Sponsor: Takeda | Conditions: Hunter Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-08-06